Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Acquisitions (2018)

Rocket Pharmaceuticals (RCKT) has disclosed Acquisitions for 1 consecutive years, with $76.3 million as the latest value for Q1 2018.

  • Quarterly Acquisitions changed N/A to $76.3 million in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $76.3 million through Dec 2018, changed N/A year-over-year, with the annual reading at $42.7 million for FY2022, N/A changed from the prior year.
  • Acquisitions hit $76.3 million in Q1 2018 for Rocket Pharmaceuticals.
  • In the past five years, Acquisitions ranged from a high of $76.3 million in Q1 2018 to a low of $76.3 million in Q1 2018.